Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


Syngenta's Duracade maize acceptance grows in US

The number of locations accepting Syngenta's genetically modified insect-resistant Agrisure Duracade (5222) maize in the US has more than doubled over the past seven months, the company points out. Some 1,652 locations accept the maize compared with 672 in July 2014. Duracade maize expresses the Bt Cry3.1 Ab toxin for the control of corn rootworms (CRWs - Diabrotica spp). It was introduced in the US last year but it has not been approved in China. Several major grain handlers refused to accept deliveries of the maize without that approval. Syngenta entered into an agreement with Gavilon Grain early last year to enable farmers to plant the maize with the assurance that there would be a market for it. Syngenta and Gavilon have since extended that agreement to 2015 with an increased number of accepting locations. "Growers challenged by CRW pressure are seeing results in the field from this technology and the response to the 'Right to Grow' programme has been very positive overall," says Chuck Lee, head of Syngenta's North American maize business.


What to read next




Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts